The impact of 18F-deoxyglucose positron emission tomography on tumor staging, treatment strategy and treatment planning for radiotherapy in a department of radiation oncology

Tumori

Volumn 90, Issue 6, 2004, Pages 579-585

  Gabriele, Pietro ^a   Malinverni, Giuseppe ^a,d   Moroni, Gian Luca ^b   Gatti, Marco ^a   Regge, Daniele ^a   Versari, Annibale ^c   Serafini, Desiderio ^c   Fraternali, Alessandro ^c   Salvo, Diana ^c  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b ASL 9   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d NONE   (Italy)

Author keywords

Positron emission tomography; Radiotherapy treatment planning; Tumor staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGE; AGED; ARTICLE; BREAST TUMOR; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; GASTROINTESTINAL TUMOR; HEMATOLOGIC MALIGNANCY; HISTOLOGY; HOSPITAL DEPARTMENT; HUMAN; IMAGING SYSTEM; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; SEX RATIO; TREATMENT PLANNING; UROGENITAL TRACT TUMOR; ADJUVANT THERAPY; BLOOD DISEASE; COMPUTER ASSISTED RADIOTHERAPY; ITALY; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; SCINTISCANNING;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; HEMATOLOGIC NEOPLASMS; HUMANS; ITALY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, ADJUVANT; UROGENITAL NEOPLASMS;

EID: 14244255982     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160409000608     Document Type: Article

References (31)

1. Hoffman FA: Metabolic changes in malignancy. In: Cancer growth and progression, Liotta LA (Ed), Kluwer Academic, Boston, 1989.
2. Gallagher BM, Fowler GS, Gutterson NI: Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of 18F-FDG. J Nucl Med, 19: 1154-1161, 1978.
3. Som P, Atkins L, Bandoyapadhyay D: A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F18): non toxic tracers for rapid tumor detection. J Nucl Med, 21: 670-675, 1980.
4. Warburg O: The Metabolism of Tumors, pp. 129-169. Richard R. Smith, Inc, New York, 1931.
5. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, Wood DE: Lung cancer proliferation correlates with F18-fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res, 6: 3837-3844, 2000.
6. Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, El-Ghazi el A, Lehmann W, Slosman DO: Standardized uptake value of 2-F18-fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol, 20: 1398-1400, 2002.
7. Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME: A tabulated summary of the FDG PET literature. J Nucl Med, 42: 1S-93S, 2001.
8. Zasadny KR, Kison PV, Quint LE, Wahl RL: Untreated lung cancer: quantification of systematic distortion of tumor size and shape on non-attenuation-corrected 18FDG PET scans. Radiology, 201: 873-876, 1996.
9. Cook GJR, Maisey MN, Fogelman I: Normal variants, artifacts and interpretation pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med, 26: 1363-1378, 1999.
10. Van de Wiele C, Lahorte C, Oyen W, Boerman O, Goethals I, Siegers G, Dierckx RA: Nuclear medicine imaging to predict response to radiotherapy: a review. Int J Radiat Oncol Biol Phys, 55: 5-15, 2003.
11. De Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK: Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol, 8: 57-60, 1997.
12. Wiedmann E, Baican B, Hertel A, Baum RP, Chow KU, Knupp B, Adams S, Hor G, Hoelzer D, Mitrou PS: Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma, 34: 545-551, 1999.
13. Romer W, Hanauske AR, Ziegler S, Thodtmann R, Weber W, Fuchs C, Enne W, Herz M, Nerl C, Garbrecht M, Schwaiger M: Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood, 91: 4464-4471, 1998.
14. Miller TR, Grigsby PW: Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys, 53: 353-359, 2002.
15. Munley MT, Marks LB, Scarfone C, Sibley GS, Patz EF Jr, Turkington TG, Jaszczak RJ, Gilland DR, Anscher MS, Coleman RE: Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer, 23: 105-114, 1999.
16. Kiffer JD, Berlangieri SU, Scott AM, Quong G, Feigen M, Schumer W, Clarke CP, Knight SR, Daniel FJ: The contribution of 18F-fluoro-deoxyglucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer, 19: 167-177, 1998.
17. Debois M, Fossard A, Vansteenkiste J, De Wever W, Verschakelen J, Bogaerts J, Gatti G, Stroobants S, Dupont P, Huyskens D, Kutcher J, Vanuytsel L: Impact of PET scan in lung cancer radiotherapy planning (Abstr n. 51). Radiother Oncol. 48: S13, 1998.
18. Nestle U, Walter K, Schmidt S, Licht N, Nieder C, Motaref B, Hellwig D, Niewald M, Ukena D, Kirsch CM, Sybrecht GW, Schnabel K: 18F-Deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis. Int J Radiat Oncol Biol Phys, 44: 593-597, 1999.
19. Erdi YE, Rosenzweig K, Erdi AK, Macapinlac HA, Hu YC, Braban LE, Humm JL, Squire OD, Chui CS, Larson SM, Yorke ED: Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol; 62: 51-60, 2002.
20. Gabriele P, Malinverni G, Munoz F, Gatti M, Delmastro E, Macias V, Scielzo G: Implementation of the 3D-CRT in prostate, head and neck and lung cancer at the IRCC of Turin. Proceedings of the VII ICRO/OGRO International Meeting, Salzburg, pp. 219-221, Monduzzi, Bologna, 2002.
21. Nishioka T, Shiga T, Shirato H, Tsukamoto E, Tsuchiya K, Kato T, Ohmori K, Yamazaki A. Aoyama H, Hashimoto S, Chang TC, Miyasaka K: Image fusion between 18FDG-PET and MRFCT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys, 53: 1051-1057, 2002.
22. Klabbers BM, de Munck JC, Slotman BJ, Langendijk HA, de Bree R, Hoekstra OS, Boellaard R, Lammertsma AA: Matching PET and CT scans of the head and neck area: development of method and validation. Med Phys, 29: 2230-2238, 2002.
23. Gross MW, Weber WA, Feldmann HJ, Bartenstein P, Schwaiger M, Molls M: F-18-Fluorodesoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys, 41: 989-995, 1998.
24. Rahn AN, Baum RP, Adamietz IA, Adams S, Sengupta S, Mose S, Bormeth SB, Hor G, Bottcher HD: Value of FDG-positron emission tomography in radiation treatment planning of head and neck tumors. Strahlenther Onkol, 174: 358-364, 1998.
25. Grigsby PW, Siegel BA, Dehdashty F: Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol, 19: 3745-3749, 2001.
26. Mutic S, Malyapa RS, Grigsby PW, Dehdashti F, Miller TR, Zoberi I, Bosch WR, Esthappan J, Low DA: PET-guided-IM-RT treatment for cervical carcinoma with positive para-aortic lymph nodes - a dose escalation treatment planning study. Int J Radiat Oncol Biol Phys, 53: 1051-1057, 2002.
27. Mutic S, Grigsby PW, Low DA, Dempsey JF, Harms WB, Laforest R, Bosch WR, Miller TR: PET-guided three-dimensional treatment planning of intracavitary gynecologic implants. Int J Radiat Oncol Biol Phys, 52: 1104-1110, 2002.
28. Beyer T, Townsend D, Blodgett T: Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med, 46: 24-34, 2002.
29. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, Krohn KA: Quantifying regional hypoxia in human tumours with positron emission tomography of 18F-fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys, 36: 417-428, 1996.
30. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ: A novel approach to overcome hypoxic tumour resistance: Cu-ATSM-guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys, 49: 1171-1182, 2001.
31. Bombardieri E, Crippa F, Rossetti C, Fazio F: The need of cost effectiveness evaluation when using high-cost equipment in National Health Service. Tumori, 83: 544-546, 1997.